 Denis Evans
Concepts (369)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognition Disorders | 19 | 2015 | 1064 | 4.240 |
Why?
| | African Americans | 18 | 2018 | 780 | 3.680 |
Why?
| | Alzheimer Disease | 19 | 2018 | 1751 | 2.750 |
Why?
| | Cognition | 14 | 2018 | 1141 | 2.620 |
Why?
| | Apolipoprotein E4 | 7 | 2018 | 208 | 2.480 |
Why?
| | Population Surveillance | 7 | 2015 | 129 | 2.220 |
Why?
| | Stroke | 6 | 2016 | 345 | 1.970 |
Why?
| | Longitudinal Studies | 18 | 2018 | 1432 | 1.590 |
Why?
| | Aging | 11 | 2017 | 1551 | 1.590 |
Why?
| | Aged | 48 | 2018 | 10156 | 1.510 |
Why?
| | Genome-Wide Association Study | 14 | 2017 | 308 | 1.280 |
Why?
| | Genetic Predisposition to Disease | 13 | 2017 | 473 | 1.280 |
Why?
| | Female | 51 | 2018 | 18107 | 1.270 |
Why?
| | Male | 48 | 2018 | 17552 | 1.260 |
Why?
| | Humans | 70 | 2018 | 30741 | 1.200 |
Why?
| | Aged, 80 and over | 33 | 2018 | 5172 | 1.190 |
Why?
| | Chicago | 15 | 2018 | 945 | 1.160 |
Why?
| | Polymorphism, Single Nucleotide | 16 | 2017 | 331 | 1.140 |
Why?
| | Depression | 6 | 2014 | 502 | 1.120 |
Why?
| | Biological Products | 2 | 2013 | 35 | 0.990 |
Why?
| | Risk Factors | 15 | 2018 | 2611 | 0.940 |
Why?
| | Incidence | 8 | 2018 | 827 | 0.900 |
Why?
| | Neuropsychological Tests | 10 | 2018 | 1278 | 0.850 |
Why?
| | Stress, Psychological | 5 | 2013 | 278 | 0.840 |
Why?
| | Memory, Episodic | 3 | 2017 | 105 | 0.830 |
Why?
| | United States | 11 | 2018 | 2467 | 0.820 |
Why?
| | Hospitalization | 2 | 2013 | 344 | 0.800 |
Why?
| | Dementia | 3 | 2017 | 509 | 0.800 |
Why?
| | Heterocyclic Compounds | 3 | 2015 | 17 | 0.790 |
Why?
| | Apolipoproteins E | 2 | 2017 | 202 | 0.770 |
Why?
| | Activities of Daily Living | 4 | 2015 | 472 | 0.710 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2017 | 16 | 0.710 |
Why?
| | Geriatric Assessment | 5 | 2015 | 230 | 0.700 |
Why?
| | Art | 1 | 2016 | 3 | 0.680 |
Why?
| | Follow-Up Studies | 9 | 2017 | 2046 | 0.680 |
Why?
| | Guidelines as Topic | 1 | 2017 | 78 | 0.670 |
Why?
| | Disease Progression | 8 | 2017 | 851 | 0.670 |
Why?
| | Mortality | 2 | 2016 | 97 | 0.670 |
Why?
| | Music | 1 | 2016 | 24 | 0.660 |
Why?
| | Diabetes Complications | 1 | 2016 | 71 | 0.640 |
Why?
| | Reading | 1 | 2016 | 41 | 0.640 |
Why?
| | African Continental Ancestry Group | 2 | 2015 | 30 | 0.630 |
Why?
| | European Continental Ancestry Group | 2 | 2015 | 66 | 0.620 |
Why?
| | Prospective Studies | 9 | 2016 | 1891 | 0.610 |
Why?
| | Health Planning | 1 | 2015 | 5 | 0.600 |
Why?
| | Body Mass Index | 2 | 2015 | 438 | 0.580 |
Why?
| | Residence Characteristics | 3 | 2015 | 222 | 0.580 |
Why?
| | Genetic Loci | 5 | 2016 | 68 | 0.580 |
Why?
| | Anxiety Disorders | 1 | 2016 | 175 | 0.580 |
Why?
| | Health Services Needs and Demand | 1 | 2015 | 69 | 0.580 |
Why?
| | Drug Monitoring | 1 | 2014 | 28 | 0.570 |
Why?
| | Social Support | 2 | 2013 | 217 | 0.570 |
Why?
| | Erythrocyte Indices | 1 | 2014 | 4 | 0.570 |
Why?
| | Anti-Retroviral Agents | 1 | 2014 | 45 | 0.560 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 19 | 0.560 |
Why?
| | Clinical Laboratory Techniques | 1 | 2014 | 39 | 0.560 |
Why?
| | Time Factors | 7 | 2017 | 1911 | 0.560 |
Why?
| | Mobility Limitation | 1 | 2015 | 99 | 0.560 |
Why?
| | Disability Evaluation | 3 | 2013 | 330 | 0.550 |
Why?
| | Memantine | 1 | 2014 | 12 | 0.550 |
Why?
| | Depressive Disorder | 1 | 2015 | 213 | 0.550 |
Why?
| | Vitamin E | 1 | 2014 | 43 | 0.550 |
Why?
| | Dopamine Agents | 1 | 2014 | 41 | 0.540 |
Why?
| | Diterpenes | 1 | 2013 | 10 | 0.530 |
Why?
| | Carbolines | 1 | 2013 | 6 | 0.530 |
Why?
| | Sleep | 1 | 2017 | 340 | 0.530 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 222 | 0.520 |
Why?
| | Antioxidants | 1 | 2014 | 70 | 0.520 |
Why?
| | Algorithms | 3 | 2015 | 421 | 0.520 |
Why?
| | Censuses | 1 | 2013 | 8 | 0.520 |
Why?
| | Carboxylic Acids | 1 | 2012 | 1 | 0.520 |
Why?
| | Imides | 1 | 2012 | 2 | 0.520 |
Why?
| | Anemia | 1 | 2014 | 91 | 0.520 |
Why?
| | Tetracycline | 1 | 2012 | 5 | 0.520 |
Why?
| | Cardiovascular Diseases | 1 | 2017 | 391 | 0.520 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2014 | 220 | 0.510 |
Why?
| | Isoxazoles | 1 | 2012 | 17 | 0.510 |
Why?
| | Imines | 1 | 2012 | 2 | 0.500 |
Why?
| | Alkaloids | 1 | 2012 | 8 | 0.500 |
Why?
| | Urban Population | 1 | 2013 | 158 | 0.490 |
Why?
| | Motor Activity | 1 | 2015 | 395 | 0.470 |
Why?
| | Alleles | 4 | 2016 | 230 | 0.460 |
Why?
| | Genotype | 8 | 2017 | 447 | 0.450 |
Why?
| | Linear Models | 3 | 2016 | 277 | 0.440 |
Why?
| | Obesity | 1 | 2014 | 322 | 0.430 |
Why?
| | Cost-Benefit Analysis | 1 | 2011 | 146 | 0.430 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 403 | 0.390 |
Why?
| | Odds Ratio | 5 | 2017 | 328 | 0.380 |
Why?
| | Cohort Studies | 11 | 2016 | 1959 | 0.370 |
Why?
| | HIV Infections | 1 | 2014 | 915 | 0.340 |
Why?
| | Molecular Structure | 4 | 2015 | 50 | 0.330 |
Why?
| | Receptors, Immunologic | 2 | 2017 | 32 | 0.320 |
Why?
| | Interviews as Topic | 3 | 2015 | 148 | 0.320 |
Why?
| | Laryngoscopes | 2 | 2016 | 7 | 0.320 |
Why?
| | Membrane Glycoproteins | 2 | 2017 | 107 | 0.310 |
Why?
| | Gold | 2 | 2015 | 5 | 0.310 |
Why?
| | Methane | 2 | 2015 | 4 | 0.310 |
Why?
| | Computer Simulation | 3 | 2017 | 246 | 0.290 |
Why?
| | Small Molecule Libraries | 2 | 2015 | 10 | 0.290 |
Why?
| | Models, Molecular | 3 | 2016 | 103 | 0.290 |
Why?
| | Computational Biology | 2 | 2014 | 32 | 0.280 |
Why?
| | Prevalence | 3 | 2015 | 546 | 0.270 |
Why?
| | Sialic Acid Binding Ig-like Lectin 3 | 2 | 2013 | 16 | 0.270 |
Why?
| | Stereoisomerism | 2 | 2013 | 21 | 0.260 |
Why?
| | Molecular Conformation | 2 | 2013 | 17 | 0.260 |
Why?
| | Forecasting | 2 | 2014 | 130 | 0.260 |
Why?
| | Cyclization | 2 | 2012 | 16 | 0.250 |
Why?
| | Disabled Persons | 2 | 2016 | 110 | 0.250 |
Why?
| | Quantitative Trait Loci | 3 | 2017 | 65 | 0.250 |
Why?
| | Cerebrovascular Disorders | 2 | 2015 | 124 | 0.240 |
Why?
| | Health Status Disparities | 2 | 2013 | 68 | 0.240 |
Why?
| | Genetic Association Studies | 3 | 2017 | 90 | 0.240 |
Why?
| | Middle Aged | 12 | 2017 | 11256 | 0.220 |
Why?
| | Confidence Intervals | 2 | 2017 | 105 | 0.210 |
Why?
| | Laryngoscopy | 2 | 2016 | 23 | 0.200 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2017 | 93 | 0.200 |
Why?
| | Microglia | 2 | 2017 | 126 | 0.190 |
Why?
| | Hypoglycemic Agents | 2 | 2016 | 76 | 0.190 |
Why?
| | Logistic Models | 3 | 2015 | 479 | 0.180 |
Why?
| | Cross-Sectional Studies | 3 | 2016 | 957 | 0.180 |
Why?
| | Models, Genetic | 2 | 2015 | 44 | 0.180 |
Why?
| | Phospholipase C gamma | 1 | 2017 | 10 | 0.180 |
Why?
| | Reimbursement Mechanisms | 1 | 2017 | 13 | 0.180 |
Why?
| | Polypharmacology | 1 | 2017 | 1 | 0.180 |
Why?
| | Instinct | 1 | 2017 | 1 | 0.180 |
Why?
| | Escape Reaction | 1 | 2017 | 4 | 0.180 |
Why?
| | Crystallography, X-Ray | 2 | 2016 | 17 | 0.170 |
Why?
| | Oxidative Stress | 2 | 2015 | 136 | 0.170 |
Why?
| | Spatial Learning | 1 | 2017 | 6 | 0.170 |
Why?
| | Insurance Coverage | 1 | 2017 | 17 | 0.170 |
Why?
| | Hypnotics and Sedatives | 1 | 2017 | 24 | 0.170 |
Why?
| | Phenotype | 5 | 2017 | 368 | 0.170 |
Why?
| | Birth Order | 1 | 2016 | 2 | 0.170 |
Why?
| | Parity | 1 | 2016 | 5 | 0.170 |
Why?
| | Reproductive Behavior | 1 | 2016 | 4 | 0.170 |
Why?
| | Reproduction | 1 | 2016 | 10 | 0.170 |
Why?
| | Immunity, Innate | 1 | 2017 | 87 | 0.170 |
Why?
| | Medicare | 2 | 2014 | 103 | 0.160 |
Why?
| | Substrate Specificity | 2 | 2016 | 37 | 0.160 |
Why?
| | Vehicle Emissions | 1 | 2016 | 2 | 0.160 |
Why?
| | Proportional Hazards Models | 2 | 2014 | 385 | 0.160 |
Why?
| | Receptor, Muscarinic M4 | 1 | 2016 | 1 | 0.160 |
Why?
| | Receptor, Muscarinic M1 | 1 | 2016 | 1 | 0.160 |
Why?
| | Mental Status Schedule | 1 | 2016 | 121 | 0.160 |
Why?
| | Conservation of Natural Resources | 1 | 2016 | 4 | 0.160 |
Why?
| | Ecosystem | 2 | 2016 | 23 | 0.160 |
Why?
| | Policy Making | 1 | 2016 | 16 | 0.160 |
Why?
| | Behavior, Animal | 1 | 2017 | 109 | 0.160 |
Why?
| | Air Pollution | 1 | 2016 | 15 | 0.160 |
Why?
| | Students, Medical | 1 | 2016 | 45 | 0.160 |
Why?
| | Hand Strength | 1 | 2016 | 62 | 0.160 |
Why?
| | Employment | 1 | 2016 | 38 | 0.160 |
Why?
| | Body Size | 1 | 2015 | 15 | 0.160 |
Why?
| | Brief Psychiatric Rating Scale | 1 | 2015 | 8 | 0.150 |
Why?
| | Ribosomes | 1 | 2015 | 3 | 0.150 |
Why?
| | Models, Theoretical | 1 | 2016 | 109 | 0.150 |
Why?
| | Acenaphthenes | 1 | 2015 | 1 | 0.150 |
Why?
| | Muscle Strength | 1 | 2016 | 134 | 0.150 |
Why?
| | Trust | 1 | 2015 | 15 | 0.150 |
Why?
| | Databases, Factual | 2 | 2014 | 372 | 0.150 |
Why?
| | Atlanto-Axial Joint | 1 | 2014 | 19 | 0.150 |
Why?
| | South Africa | 1 | 2014 | 17 | 0.150 |
Why?
| | Antineoplastic Agents | 2 | 2015 | 321 | 0.150 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 38 | 0.140 |
Why?
| | Forkhead Transcription Factors | 1 | 2014 | 28 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 1 | 2015 | 74 | 0.140 |
Why?
| | Retrospective Studies | 2 | 2014 | 3456 | 0.140 |
Why?
| | Longevity | 1 | 2014 | 34 | 0.140 |
Why?
| | Drug Discovery | 1 | 2014 | 30 | 0.140 |
Why?
| | Proteins | 1 | 2015 | 91 | 0.140 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 161 | 0.140 |
Why?
| | Spinal Fractures | 1 | 2014 | 61 | 0.140 |
Why?
| | Risk | 1 | 2015 | 232 | 0.140 |
Why?
| | Intelligence Tests | 1 | 2014 | 18 | 0.140 |
Why?
| | Interview, Psychological | 1 | 2014 | 45 | 0.140 |
Why?
| | Transcriptome | 1 | 2014 | 80 | 0.140 |
Why?
| | Probability | 1 | 2014 | 107 | 0.140 |
Why?
| | Leukemia Virus, Murine | 1 | 2013 | 2 | 0.140 |
Why?
| | Viral Load | 1 | 2014 | 211 | 0.140 |
Why?
| | Transduction, Genetic | 1 | 2013 | 22 | 0.140 |
Why?
| | Recombination, Genetic | 1 | 2013 | 19 | 0.140 |
Why?
| | Intubation, Intratracheal | 1 | 2014 | 66 | 0.140 |
Why?
| | Treatment Failure | 1 | 2014 | 188 | 0.140 |
Why?
| | Luminescent Proteins | 1 | 2013 | 12 | 0.140 |
Why?
| | Movement | 1 | 2014 | 167 | 0.140 |
Why?
| | Genes, Reporter | 1 | 2013 | 33 | 0.140 |
Why?
| | Adult | 7 | 2016 | 9760 | 0.130 |
Why?
| | Clinical Competence | 1 | 2016 | 268 | 0.130 |
Why?
| | Overweight | 1 | 2014 | 64 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2015 | 115 | 0.130 |
Why?
| | White Matter | 1 | 2015 | 124 | 0.130 |
Why?
| | Religion and Psychology | 1 | 2013 | 26 | 0.130 |
Why?
| | Esters | 1 | 2012 | 1 | 0.130 |
Why?
| | Alkylation | 1 | 2012 | 1 | 0.130 |
Why?
| | Hemeproteins | 1 | 2012 | 1 | 0.130 |
Why?
| | Memory | 1 | 2015 | 333 | 0.130 |
Why?
| | Cerebral Cortex | 1 | 2015 | 203 | 0.130 |
Why?
| | Macrophage Activation | 1 | 2012 | 13 | 0.130 |
Why?
| | Personal Satisfaction | 1 | 2013 | 50 | 0.130 |
Why?
| | Life Change Events | 1 | 2012 | 42 | 0.130 |
Why?
| | Age of Onset | 4 | 2014 | 115 | 0.130 |
Why?
| | Peptide Fragments | 1 | 2013 | 121 | 0.130 |
Why?
| | Gait | 1 | 2017 | 388 | 0.130 |
Why?
| | Monocytes | 1 | 2013 | 105 | 0.130 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 594 | 0.130 |
Why?
| | Environmental Policy | 1 | 2012 | 2 | 0.130 |
Why?
| | Air | 1 | 2012 | 6 | 0.130 |
Why?
| | Brain | 4 | 2016 | 1574 | 0.120 |
Why?
| | Chemistry Techniques, Synthetic | 1 | 2012 | 1 | 0.120 |
Why?
| | Spirituality | 1 | 2013 | 58 | 0.120 |
Why?
| | Socioeconomic Factors | 4 | 2015 | 362 | 0.120 |
Why?
| | Selection, Genetic | 1 | 2012 | 6 | 0.120 |
Why?
| | Anomie | 1 | 2012 | 4 | 0.120 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2014 | 386 | 0.120 |
Why?
| | Receptors, Complement | 1 | 2012 | 5 | 0.120 |
Why?
| | Schistosoma mansoni | 1 | 2012 | 42 | 0.120 |
Why?
| | Temperature | 1 | 2012 | 84 | 0.120 |
Why?
| | Diet, Mediterranean | 1 | 2013 | 53 | 0.120 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2012 | 59 | 0.120 |
Why?
| | Gene Expression Regulation | 1 | 2014 | 348 | 0.120 |
Why?
| | Life Style | 1 | 2014 | 208 | 0.120 |
Why?
| | Macrophages | 1 | 2012 | 114 | 0.120 |
Why?
| | Feeding Behavior | 1 | 2013 | 123 | 0.120 |
Why?
| | Amyloid beta-Peptides | 1 | 2013 | 229 | 0.120 |
Why?
| | Social Environment | 1 | 2012 | 93 | 0.110 |
Why?
| | Attitude to Health | 1 | 2012 | 116 | 0.110 |
Why?
| | Community Health Planning | 1 | 2011 | 21 | 0.110 |
Why?
| | Age Factors | 4 | 2015 | 941 | 0.110 |
Why?
| | Decision Making | 1 | 2012 | 228 | 0.100 |
Why?
| | Hypertension | 1 | 2012 | 272 | 0.100 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 386 | 0.100 |
Why?
| | Parkinson Disease | 2 | 2016 | 1136 | 0.090 |
Why?
| | Animals | 5 | 2017 | 5221 | 0.090 |
Why?
| | Plaque, Amyloid | 3 | 2015 | 144 | 0.090 |
Why?
| | Linkage Disequilibrium | 2 | 2017 | 50 | 0.080 |
Why?
| | Protein Interaction Maps | 2 | 2017 | 18 | 0.080 |
Why?
| | Ligands | 2 | 2015 | 56 | 0.070 |
Why?
| | Mice | 3 | 2017 | 1843 | 0.070 |
Why?
| | Gene Frequency | 2 | 2017 | 86 | 0.070 |
Why?
| | HEK293 Cells | 2 | 2015 | 87 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2017 | 694 | 0.070 |
Why?
| | Mice, Inbred C57BL | 2 | 2017 | 538 | 0.060 |
Why?
| | Haplotypes | 2 | 2012 | 68 | 0.060 |
Why?
| | Exome | 1 | 2017 | 9 | 0.040 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2017 | 56 | 0.040 |
Why?
| | Young Adult | 2 | 2016 | 2249 | 0.040 |
Why?
| | Benzazepines | 1 | 2017 | 10 | 0.040 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 1 | 2017 | 5 | 0.040 |
Why?
| | Photic Stimulation | 1 | 2017 | 54 | 0.040 |
Why?
| | Amino Acid Sequence | 1 | 2017 | 252 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 2017 | 19 | 0.040 |
Why?
| | Maternal Age | 1 | 2016 | 18 | 0.040 |
Why?
| | Acoustic Stimulation | 1 | 2017 | 67 | 0.040 |
Why?
| | Oncogene Protein v-akt | 1 | 2016 | 14 | 0.040 |
Why?
| | Fertility | 1 | 2016 | 16 | 0.040 |
Why?
| | Manikins | 1 | 2016 | 7 | 0.040 |
Why?
| | Molecular Sequence Annotation | 1 | 2016 | 8 | 0.040 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2016 | 28 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 183 | 0.040 |
Why?
| | Imidazoles | 1 | 2017 | 74 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2016 | 81 | 0.040 |
Why?
| | Geographic Information Systems | 1 | 2016 | 4 | 0.040 |
Why?
| | Allosteric Site | 1 | 2016 | 1 | 0.040 |
Why?
| | Nicotinic Acids | 1 | 2016 | 3 | 0.040 |
Why?
| | Crystallization | 1 | 2016 | 6 | 0.040 |
Why?
| | Appalachian Region | 1 | 2016 | 1 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2016 | 51 | 0.040 |
Why?
| | Drug Inverse Agonism | 1 | 2016 | 2 | 0.040 |
Why?
| | Allosteric Regulation | 1 | 2016 | 6 | 0.040 |
Why?
| | Acetylcholine | 1 | 2016 | 13 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2016 | 18 | 0.040 |
Why?
| | Thiophenes | 1 | 2016 | 14 | 0.040 |
Why?
| | Air Pollutants | 1 | 2016 | 12 | 0.040 |
Why?
| | Static Electricity | 1 | 2016 | 45 | 0.040 |
Why?
| | Biomedical Research | 1 | 2017 | 85 | 0.040 |
Why?
| | Embryo, Nonmammalian | 1 | 2015 | 9 | 0.040 |
Why?
| | Waist-Hip Ratio | 1 | 2015 | 17 | 0.040 |
Why?
| | Zebrafish | 1 | 2015 | 22 | 0.040 |
Why?
| | Surface Properties | 1 | 2016 | 140 | 0.040 |
Why?
| | Chromosome Mapping | 1 | 2015 | 61 | 0.040 |
Why?
| | Equipment Design | 1 | 2016 | 204 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 91 | 0.040 |
Why?
| | Schizophrenia | 1 | 2016 | 80 | 0.040 |
Why?
| | Acetamides | 1 | 2015 | 8 | 0.040 |
Why?
| | Endophenotypes | 1 | 2015 | 13 | 0.040 |
Why?
| | Chromosomes, Human | 1 | 2015 | 7 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2015 | 18 | 0.040 |
Why?
| | Hep G2 Cells | 1 | 2015 | 3 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2015 | 11 | 0.040 |
Why?
| | Nanofibers | 1 | 2015 | 2 | 0.040 |
Why?
| | Coordination Complexes | 1 | 2015 | 4 | 0.040 |
Why?
| | Pregnancy | 1 | 2016 | 452 | 0.040 |
Why?
| | Glutathione | 1 | 2015 | 30 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2015 | 43 | 0.040 |
Why?
| | Odontoid Process | 1 | 2014 | 10 | 0.040 |
Why?
| | MCF-7 Cells | 1 | 2015 | 18 | 0.040 |
Why?
| | Head Movements | 1 | 2014 | 9 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2015 | 34 | 0.040 |
Why?
| | Fluorouracil | 1 | 2015 | 89 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2014 | 12 | 0.040 |
Why?
| | Receptors, Kainic Acid | 1 | 2014 | 4 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2014 | 56 | 0.040 |
Why?
| | Fluoroscopy | 1 | 2014 | 55 | 0.040 |
Why?
| | Cell Adhesion Molecules | 1 | 2014 | 42 | 0.040 |
Why?
| | Rats | 1 | 2017 | 954 | 0.040 |
Why?
| | Heterozygote | 1 | 2014 | 106 | 0.040 |
Why?
| | Cell Survival | 1 | 2015 | 182 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2015 | 126 | 0.040 |
Why?
| | Alternative Splicing | 1 | 2013 | 31 | 0.030 |
Why?
| | Neurofibrillary Tangles | 1 | 2015 | 174 | 0.030 |
Why?
| | Exons | 1 | 2013 | 46 | 0.030 |
Why?
| | Antipsychotic Agents | 1 | 2014 | 90 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2013 | 59 | 0.030 |
Why?
| | Spinal Cord | 1 | 2014 | 99 | 0.030 |
Why?
| | Protein Structure, Tertiary | 1 | 2013 | 87 | 0.030 |
Why?
| | Virus Integration | 1 | 2013 | 9 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2013 | 97 | 0.030 |
Why?
| | Gene Transfer Techniques | 1 | 2013 | 37 | 0.030 |
Why?
| | HLA-D Antigens | 1 | 2013 | 3 | 0.030 |
Why?
| | Dextrans | 1 | 2013 | 6 | 0.030 |
Why?
| | Genetic Variation | 1 | 2014 | 117 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 296 | 0.030 |
Why?
| | Stem Cells | 1 | 2014 | 53 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 109 | 0.030 |
Why?
| | Radionuclide Imaging | 1 | 2013 | 58 | 0.030 |
Why?
| | Health Status | 1 | 2015 | 252 | 0.030 |
Why?
| | Genetic Vectors | 1 | 2013 | 69 | 0.030 |
Why?
| | Cadaver | 1 | 2014 | 354 | 0.030 |
Why?
| | Aniline Compounds | 1 | 2013 | 40 | 0.030 |
Why?
| | Thiazoles | 1 | 2013 | 39 | 0.030 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2013 | 8 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2016 | 875 | 0.030 |
Why?
| | Genetic Testing | 1 | 2013 | 76 | 0.030 |
Why?
| | Diet Surveys | 1 | 2013 | 24 | 0.030 |
Why?
| | Ovum | 1 | 2012 | 5 | 0.030 |
Why?
| | Schistosomiasis | 1 | 2012 | 8 | 0.030 |
Why?
| | Th2 Cells | 1 | 2012 | 31 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2013 | 96 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2012 | 35 | 0.030 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2013 | 41 | 0.030 |
Why?
| | Phagocytes | 1 | 2012 | 24 | 0.030 |
Why?
| | Lewy Bodies | 1 | 2014 | 184 | 0.030 |
Why?
| | Receptor, EphA1 | 1 | 2012 | 4 | 0.030 |
Why?
| | Monomeric Clathrin Assembly Proteins | 1 | 2012 | 7 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2012 | 19 | 0.030 |
Why?
| | Multilevel Analysis | 1 | 2012 | 7 | 0.030 |
Why?
| | Immunologic Factors | 1 | 2012 | 50 | 0.030 |
Why?
| | Regression Analysis | 1 | 2013 | 323 | 0.030 |
Why?
| | Cytoskeletal Proteins | 1 | 2012 | 32 | 0.030 |
Why?
| | Brain Mapping | 1 | 2013 | 196 | 0.030 |
Why?
| | Apoptosis | 1 | 2014 | 291 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2012 | 41 | 0.030 |
Why?
| | Neuroimaging | 1 | 2013 | 122 | 0.030 |
Why?
| | Cerebral Infarction | 1 | 2013 | 158 | 0.030 |
Why?
| | Self Report | 1 | 2013 | 217 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2012 | 96 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2012 | 369 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2012 | 91 | 0.030 |
Why?
| | Signal Transduction | 1 | 2014 | 582 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2012 | 79 | 0.030 |
Why?
| | Liver | 1 | 2012 | 216 | 0.030 |
Why?
| | Blood Pressure | 1 | 2012 | 250 | 0.030 |
Why?
| | Cervical Vertebrae | 1 | 2014 | 330 | 0.030 |
Why?
| | Cytokines | 1 | 2012 | 348 | 0.030 |
Why?
| | Educational Status | 1 | 2012 | 285 | 0.030 |
Why?
| | Models, Biological | 1 | 2013 | 428 | 0.030 |
Why?
| | Risk Assessment | 1 | 2012 | 804 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2013 | 1244 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2012 | 1233 | 0.020 |
Why?
|
|
Evans's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|